Drug-Eluting Balloons Bounce into Global Market

Monday 29 October 2012, Amsterdam

It looks as though drug-eluting balloons already widely used in Europe are set to burst into the global market, as heart conditions become a more common problem, states a new report by healthcare experts.

The new report looks at peripheral Vascular Disease (PVD), which involves the buildup of plaque, and the subsequent narrowing or blockages in arteries, and insufficient blood flow. The growth of the peripheral vascular devices market is being driven by rising incidence rates of PVD, due to conditions such as diabetes, end-stage renal disease and obesity becoming more widespread.

PVD can be treated surgically or via minimally invasive catheter-based techniques.  Minimally invasive procedures such as Percutaneous Transluminal Angioplasty (PTA) and Endovascular aneurysm repair (EVAR) to treat abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs) have become widely adopted, due to improved patient comfort, faster recovery and lower morbidity rates. A broad trend is seeing many patients opt for less invasive procedures over traditional open surgery, driving demand for devices used in these procedures, such as Percutaneous Transluminal Angioplasty (PTA) peripheral Drug- Eluting Balloons (DEBs), peripheral vascular stents, stent grafts and PTA balloons.

The high risk of stent thrombosis means that patients who undergo vascular surgery are often prescribed anti-platelet therapy to prevent clot formation. However, this is unsuitable for elderly patients, pregnant women and individuals at high risk of bleeding. Luckily, DEBs require a shorter regimen of antiplatelet therapy than other treatment options, requiring only three months of therapy, rather than the standard 12 months required for Drug-Eluting Stents (DESs), due to the lower associated risk of thrombosis. DEBs are also able to overcome the various issues associated with stents, such as high risk of restenosis, incomplete drug delivery and limited area coverage for drug delivery, which has increased the demand for DEBs around the world.

While DEBs are accepted by most physicians in Europe, they are yet to be approved in the  US, Canada and Japan. These countries offer strong opportunities for market growth if companies can successfully expand here.

This report examines the market and competitive landscape and trends for the eight market segments: stent grafts, peripheral vascular stents, Percutaneous Transluminal Angioplasty (PTA) balloons, peripheral embolic protection devices, Inferior Vena Cava Filters (IVCFs), synthetic surgical grafts, peripheral guidewires and PTA peripheral Drug-Eluting Balloons (DEBs). It provides comprehensive information on the key trends affecting these segments and analyzes the market dynamics. The report also looks at the pipeline products in each segment and gives details regarding important M&A activity.

The report is built using data and information sourced from proprietary databases, primary and secondary research and analysis.